Kosmalski et al., 2023 - Google Patents
Pharmacological support for the treatment of obesity—present and futureKosmalski et al., 2023
View HTML- Document ID
- 11718658995118191646
- Author
- Kosmalski M
- Deska K
- Bąk B
- Różycka-Kosmalska M
- Pietras T
- Publication year
- Publication venue
- Healthcare
External Links
Snippet
Obesity is a growing civilization problem, associated with a number of negative health consequences affecting almost all tissues and organs. Currently, obesity treatment includes lifestyle modifications (including diet and exercise), pharmacologic therapies, and in some …
- 230000000144 pharmacologic effect 0 title description 4
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Kosmalski et al. | Pharmacological support for the treatment of obesity—present and future | |
| Michałowska et al. | Incretin hormones in obesity and related cardiometabolic disorders: the clinical perspective | |
| Rentzeperi et al. | Sex differences in response to treatment with glucagon-like peptide 1 receptor agonists: opportunities for a tailored approach to diabetes and obesity care | |
| Gjermeni et al. | Obesity–an update on the basic pathophysiology and review of recent therapeutic advances | |
| El Meouchy et al. | Hypertension related to obesity: pathogenesis, characteristics and factors for control | |
| Popoviciu et al. | Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials | |
| Nevola et al. | GLP-1 receptor agonists in non-alcoholic fatty liver disease: current evidence and future perspectives | |
| Szczesnowicz et al. | Do GLP-1 analogs have a place in the treatment of PCOS? New insights and promising therapies | |
| Górriz et al. | GLP-1 receptor agonists and diabetic kidney disease: a call of attention to nephrologists | |
| Artasensi et al. | Obesity and type 2 diabetes: adiposopathy as a triggering factor and therapeutic options | |
| Parida et al. | Adiponectin, obesity, and cancer: clash of the bigwigs in health and disease | |
| Wilbon et al. | GLP1 receptor agonists—effects beyond obesity and diabetes | |
| Farhadipour et al. | The function of gastrointestinal hormones in obesity—implications for the regulation of energy intake | |
| Roh et al. | Hormonal gut–brain signaling for the treatment of obesity | |
| Mahgoub et al. | An update on the molecular and cellular basis of pharmacotherapy in type 2 diabetes mellitus | |
| González-García et al. | Glucagon, GLP-1 and thermogenesis | |
| Pelle et al. | Role of a dual glucose-dependent insulinotropic peptide (GIP)/glucagon-like peptide-1 receptor agonist (twincretin) in glycemic control: from pathophysiology to treatment | |
| Hu et al. | A review and meta-analysis of the safety and efficacy of using glucagon-like peptide-1 receptor agonists | |
| Heo et al. | Current progress in pharmacogenetics of second-line antidiabetic medications: towards precision medicine for type 2 diabetes | |
| Lee et al. | Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease | |
| Palanisamy et al. | Systematic review of efficacy and safety of newer antidiabetic drugs approved from 2013 to 2017 in controlling HbA1c in diabetes patients | |
| Jonik et al. | Gastrointestinal Incretins—Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-like Peptide-1 (GLP-1) beyond Pleiotropic Physiological Effects Are Involved in Pathophysiology of Atherosclerosis and Coronary Artery Disease—State of the Art | |
| Wan et al. | GLP-1R signaling and functional molecules in incretin therapy | |
| Aguilar-Ballester et al. | Therapies for the treatment of cardiovascular disease associated with type 2 diabetes and dyslipidemia | |
| Sztanek et al. | New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists |